The collaboration between the two companies reflects ongoing efforts to enhance drug development, the CEO of Immunai said.

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

BTIG analyst Julian Harrison maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target of $51.00. Julian Harrison gave his rating based on several ...

First place in the NFL's most competitive division, the NFC North, is on the line in Week 9 on Sunday when the 6-1 Detroit Lions square off with the 6-2 Green Bay Packers at Lambeau Field.

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally administered, brain penetrant inhibitor of PRMT5 MORRISVILLE, N.C., Oct. 25, ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Amit Thackeray's electoral debut in Mahim marks a high-stakes, triangular contest against seasoned rivals from Shiv Sena factions Mumbai: The Mahim assembly constituency in Central Mumbai could ...

Enables ATX-559 Phase 1 study in solid tumor patients with a focus on BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability (MSI-H) and/or deficient mismatch repair ...

RESEARCH TRIANGLE PARK, N.C, Oct. 22, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating ...